Trials / Completed
CompletedNCT02688868
Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 )
The Safety and Effectiveness Evaluation of New Specifications (2.25mm) of FirehawkTM Sirolimus Target-eluting Coronary Stent System in the Treatment of Coronary Heart Disease: a Prospective, Multicenter, Single-group Study.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evalute the clinical safety and effectiveness of released specification (2.25mm) of FirehawkTM Sirolimus target-eluting coronary stent system.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | FirehawkTM 2.25mm | Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2015-12-01
- Completion
- 2020-12-01
- First posted
- 2016-02-23
- Last updated
- 2023-10-23
- Results posted
- 2020-02-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02688868. Inclusion in this directory is not an endorsement.